Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
Healthcare
$9.15 -2.63%
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
52W Low $4.16High $11.66
Volume 2.15M
Average 1.76M
Income Statement
Follow revenue through to earnings.
Revenue
$68.56M
FY 2025 · Annual
-7.6% YoYOperating Income
-$468.02M
FY 2025 · Annual
Net Income
-$437.99M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.62B | 86.18M | 74.21M | 68.56M |
| Cost of Revenue | 513.87M | 620.97M | 572.83M | 478.65M | 11.71M |
| Gross Profit | 581.54M | 994.83M | (486.65M) | (404.44M) | 56.85M |
| Gross Margin | 53.1% | 61.6% | -564.7% | -545.0% | 82.9% |
| Research & Development | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 92.07M |
| Operating Expenses | 160.79M | 161.76M | 197.66M | 182.73M | 524.87M |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBITDA | 555.61M | 761.06M | (641.64M) | (508.91M) | (426.09M) |
| EBITDA Margin | 50.7% | 47.1% | -744.5% | -685.8% | -621.5% |
| Operating Income | 420.75M | 833.07M | (684.31M) | (587.17M) | (468.02M) |
| Operating Margin | 38.4% | 51.6% | -794.0% | -791.3% | -682.7% |
| Interest Income | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 129.05M | (78.79M) | 56.11M | 64.06M | 30.25M |
| Income Before Tax | 549.8M | 754.28M | (628.19M) | (523.11M) | (437.77M) |
| Pre-Tax Margin | 50.2% | 46.7% | -728.9% | -704.9% | -638.6% |
| Income Tax Expense | 21.22M | 238.44M | (13.08M) | (1.15M) | 217K |
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Net Margin | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
| EPS (Basic) | 4.07 | 3.89 | (4.59) | (3.83) | (3.16) |
| EPS (Diluted) | 3.96 | 3.83 | (4.59) | (3.83) | (3.16) |
| 129.88M | 132.61M | 134.13M | 136.25M | 138.52M | |
| 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
VIR Earnings Waterfall · TTM
NASDAQ:VIR · Revenue to Net Income
Key Ratios
EPS$-3.13
Gross Margin-15118.2%
Net Margin89062.2%
P/E Ratio-2.6
P/S Ratio-10408.7
Analysis
$65.5M of revenue converted into -$442.7M of net income for the selected period. Gross margin is -15118.2% and net margin is 89062.2%, showing how much revenue survives after costs and taxes. EPS is $-3.13, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B5 | 424B5 filing | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 6, 2026 |
How much revenue does VIR generate?
Vir Biotechnology, Inc. (VIR) reported $68.56M of revenue in fiscal 2025.
Is VIR profitable?
Vir Biotechnology, Inc. (VIR) reported -$437.99M of net income, with a net margin of -638.9%.
Continue the stock analysis
Jump to another research area for this company.